This page shows the latest pegfilgrastim news and features for those working in and with pharma, biotech and healthcare.
drug Herceptin (trastuzumab) and Amgen's long-acting white cell booster Neulasta (pegfilgrastim) last August at the request of the EMA.
white cell booster Neulasta (pegfilgrastim) at the request of the EMA.
The biosimilar is also under review in Europe. Meanwhile, Novartis confirmed that it will have to carry out a new clinical trial on its biosimilar version of Amgen's Neulasta (pegfilgrastim),
The company has several other biosimilars in clinical development, including copycat versions of Humira, Roche's MabThera/Rituxan (rituximab), Amgen's Epogen (epoetin alfa) and Neulasta (pegfilgrastim) and Johnson &Johnson's
The European Medicines Agency (EMA) has now started its review of the Neulasta (pegfilgrastim) biosimilar - a long-acting granulocyte colony-stimulating factor (GCSF) that is used to prevent low white cell
Neulasta (pegfilgrastim) is a long-acting granulocyte colony stimulating factor (G-CSF) that is used to bolster white cells in patients undergoing chemotherapy for cancer, and remains one of Amgen's
More from news
Approximately 1 fully matching, plus 21 partially matching documents found.
WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...